AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization

ANAPTYSBIO, INC

2024-Q1 EPS reported -$1.64 revenue$7,179,000

Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.
Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.
Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.
Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

ANAPTYSBIO, INC reported first quarter ended March 31, 2024 results: revenue $7.2 million.

Period: first quarter ended March 31, 2024
Revenue: $7.2 million
Result: reported results

Exact text from the filing

activities as well as a one-time non-operating cash payment of $10.9 million during the quarter. ◦ Reiterating cash runway through year-end 2026 • Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three months ended March 31, 2023. The change is due primarily to increased royalties

View on SEC.gov

Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.